Literature DB >> 8862004

Multidrug resistance evaluation by confocal microscopy in primary urothelial cancer explant colonies.

A J Cooper1, M C Hayes, P M Duffy, C L Davies, C J Smart.   

Abstract

Assessing functional multidrug resistance (MDR) status in clinical biopsy material using drug autofluorescence has potential applications to clinical management. The small size of many cystoscopy specimens has led us to develop, as an alternative to flow cytometry, a protocol for studying epirubicin accumulation in adherent colonies of primary bladder cancer cells viewed live and in situ by confocal microscopy. The limitations to quantitation inherent in this technique are compensated for by preservation of cellular organisation and the elimination of non-malignant cells. Biopsy material is disaggregated and explanted into culture-grade petri dishes. After incubation for three to seven days plaques of epithelial cells have developed. Classical patterns of sensitive and resistant drug distribution are observed. Cells of the rolled edges of the colony accumulate more drug than those of the inner epithelial monolayer. Some central areas of larger colonies give the appearance of drug arrested at the intercellular junctions to give a fenestrated pattern. These observations contribute to the understanding of mechanisms in MDR as well as forming the basis for a clinical urological MDR evaluation protocol.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862004     DOI: 10.1007/bf00744210

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  10 in total

1.  Stable cell membrane labelling.

Authors:  P K Horan; S E Slezak
Journal:  Nature       Date:  1989-07-13       Impact factor: 49.962

2.  Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy.

Authors:  J E Gervasoni; S Z Fields; S Krishna; M A Baker; M Rosado; K Thuraisamy; A A Hindenburg; R N Taub
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

3.  The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.

Authors:  G J Zaman; M J Flens; M R van Leusden; M de Haas; H S Mülder; J Lankelma; H M Pinedo; R J Scheper; F Baas; H J Broxterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

Review 4.  How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture.

Authors:  M M Gottesman
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

5.  Multi-drug resistance of a doxorubicin-resistant bladder cancer cell line.

Authors:  J W Floyd; C W Lin; G R Prout
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

6.  Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A.

Authors:  H M Coley; P R Twentyman; P Workman
Journal:  Biochem Pharmacol       Date:  1989-12-15       Impact factor: 5.858

7.  The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent.

Authors:  J P Long; G R Prout; Y K Wong; C W Lin
Journal:  J Urol       Date:  1990-05       Impact factor: 7.450

8.  The drug resistance-related protein LRP is the human major vault protein.

Authors:  G L Scheffer; P L Wijngaard; M J Flens; M A Izquierdo; M L Slovak; H M Pinedo; C J Meijer; H C Clevers; R J Scheper
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

9.  Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.

Authors:  P Maslak; S Hegewisch-Becker; L Godfrey; M Andreeff
Journal:  Cytometry       Date:  1994-09-01

10.  Flow cytometric analysis of Hoechst 33342 uptake as an indicator of multi-drug resistance in human lung cancer.

Authors:  S A Morgan; J V Watson; P R Twentyman; P J Smith
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

  10 in total
  2 in total

1.  Furosemide reverses multidrug resistance status in bladder cancer cells in vitro.

Authors:  A G Speers; B A Lwaleed; J M Featherstone; B J Sallis; A J Cooper
Journal:  J Clin Pathol       Date:  2006-03-23       Impact factor: 3.411

Review 2.  Epirubicin: a review of its intravesical use in superficial bladder cancer.

Authors:  S V Onrust; L R Wiseman; K L Goa
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 4.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.